Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

被引：0
|
作者：
April W. Armstrong [1 ]
Ahmed M. Soliman [2 ]
Paolo Gisondi [3 ]
Siran Fang [2 ]
Manish Patel [2 ]
Bruce Strober [4 ]
机构：
[1] University of Southern California,Department of Dermatology, Keck School of Medicine
[2] AbbVie Inc.,Department of Medicine, Section of Dermatology and Venereology
[3] University of Verona,Department of Dermatology
[4] Yale University,undefined
[5] Central Connecticut Dermatology,undefined
来源：
Dermatology and Therapy | 2024年 / 14卷 / 11期
关键词：
Deucravacitinib; Matching-adjusted indirect comparison; Plaque psoriasis; Risankizumab;
D O I：
10.1007/s13555-024-01293-y
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3071 / 3081
页数：10
相关论文
共 50 条
  • [41] ASSESSMENT OF THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS RISANKIZUMAB FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN THE UK
    Moreno, S.
    Walsh, S.
    Khanna, P. J.
    Jain, M.
    Tanova-Yotova, N.
    VALUE IN HEALTH, 2022, 25 (12) : S89 - S89
  • [42] Biological treatments for moderate-to-severe psoriasis: indirect comparison
    Galvan-Banqueri, M.
    Marin Gil, R.
    Santos Ramos, B.
    Bautista Paloma, F. J.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (02) : 121 - 130
  • [43] Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
    Hannah A. Blair
    Drugs, 2020, 80 : 1505 - 1505
  • [44] Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
    Heydendael, VMR
    Spuls, PI
    Opmeer, BC
    de Borgie, CAJM
    Reitsma, JB
    Goldschmidt, WFM
    Bossuyt, PMM
    Bos, JD
    de Rie, MA
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07): : 658 - 665
  • [45] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Prieto-Perez, Rocio
    Llamas-Velasco, Mar
    Cabaleiro, Teresa
    Solano-Lopez, Guillermo
    Marquez, Beatriz
    Roman, Manuel
    Ochoa, Dolores
    Talegon, Maria
    Dauden, Esteban
    Abad-Santos, Francisco
    PHARMACOGENOMICS, 2017, 18 (02) : 157 - 164
  • [46] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Dauden, E.
    Prieto-Perez, R.
    Llamas-Velasco, M.
    Cabaleiro, T.
    Abad-Santos, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S188 - S188
  • [47] Treatment of moderate-to-severe plaque psoriasis
    Salgo, R.
    Thaci, D.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (06): : 701 - 711
  • [48] Indirect comparison of ixekizumab versus tildrakizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis
    Gottlieb, Alice
    Saure, Daniel
    Wilhelm, Stefan
    Dossenbach, Martin
    Thaci, Diamant
    Smith, Saxon D.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB82 - AB82
  • [49] Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis
    Gordon, K. B.
    Lebwohl, M.
    Papp, K. A.
    Bachelez, H.
    Wu, J. J.
    Langley, R. G.
    Blauvelt, A.
    Kaplan, B.
    Shah, M.
    Zhao, Y.
    Sinvhal, R.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 466 - 475
  • [50] Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
    Mease, Philip J.
    Warren, Richard B.
    Nash, Peter
    Grouin, Jean-Marie
    Lyris, Nikos
    Willems, Damon
    Taieb, Vanessa
    Eells, Jason
    Mcinnes, Iain B.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1403 - 1412
12345